San Rocco Therapeutics Unveils Promising “MiNiRoLu” Gene Therapy Data at ASGCT

According to the company, the SRT8 “MiNiRoLu” vector demonstrated approximately 30% higher functional titer, 35% greater transduction efficiency, and roughly 40% higher β-globin expression compared to an earlier lentiviral platform known as TNS9.3.55. Investigators also reported a favorable genomic integration profile, an important safety consideration in lentiviral gene therapy development.

San Rocco is also positioning itself as a lower-cost alternative in a gene therapy market increasingly criticized for multi-million-dollar pricing models. Company executives suggested total treatment costs for MiNiRoLu could potentially fall below $1 million, compared to currently approved therapies that often exceed $2 million per patient.